Featured Research

from universities, journals, and other organizations

Ibrutinib has 'unprecedented' impact on mantle cell lymphoma

Date:
December 14, 2012
Source:
University of Texas M. D. Anderson Cancer Center
Summary:
An international study of ibrutinib in people with relapsed or refractory mantle cell lymphoma (MCL) continues to show unprecedented and durable results with few side effects.

An international study of ibrutinib in people with relapsed or refractory mantle cell lymphoma (MCL) continues to show unprecedented and durable results with few side effects.

Related Articles


Researchers from The University of Texas MD Anderson Cancer Center presented interim findings of the multi-center Phase 2 study December 16 at the 54th American Society of Hematology Annual Meeting and Exposition.

"I believe we are witnessing a breakthrough in mantle cell lymphoma. This is great news for patients," said Michael Wang, M.D., associate professor in MD Anderson's Departments of Lymphoma and Myeloma and Stem Cell Transplantation and Cellular Therapy. Wang is lead author of the study.

Wang, director of the mantle cell lymphoma (MCL) program at MD Anderson, has spent the past 12 years researching the disease, including clinical trials of proteasome inhibitors, immune-modulating agents and an mTOR inhibitor.

"In a heavily treated relapsed or refractory population, oral ibrutinib induced a response rate as high as 70 percent -- better than any other single agent ever tested in MCL," he said. "The response is durable with a long progression-free survival. "

Dangerous disease presents treatment challenges

MCL is a rare and aggressive B-cell subtype of non-Hodgkin lymphoma that, according to the Leukemia and Lymphoma Society, accounts for 6 percent of non-Hodgkin cases. Despite high response rates to initial combination-drug chemotherapy, which is highly toxic, patients often relapse.

Bruton's tyrosine kinase is a mediator of B cell receptor signaling, which is essential for normal B-cell development. Ibrutinib inhibits Bruton's tyrosine kinase (BTK), causing cell death and decreasing cellular migration and adhesion in malignant B-cells.

"The foundation for this clinical success is based on biology," Wang said. "The B-cell receptor pathway is critical in B-cell lymphoma. BTK is the driver molecule in this pathway, and ibrutinib targets the BTK molecule."

Oral medication

Preliminary results reported at ASH in 2011 included 51 patients and demonstrated ibrutinib can achieve rapid response, including complete response, in relapsed and resistant MCL.

To date, 115 people have enrolled in the study. Of these patients, 110 were evaluated for the drug's efficacy. Patients had a median age of 68 years, time since diagnosis of 42 months, three prior treatments and 77 percent had stage 4 disease.

Ibrutinib was given orally at 560 mg daily in continuous 28-day cycles until disease progression.

Strong results, low toxicity

With a median follow-up period of 9.2 months, overall response rate was 68 percent, and complete remission rate was 22 percent.

Responses increased with longer time on study treatment:

* Median time to partial response was two months

* Median time to complete remission was four months

* Median time on treatment was six months

* 53 percent of subjects remain on treatment

Response was even more dramatic in the 51 original patients with:

* Overall response rate of 75 percent

* Complete remissions in 39 percent

* Median time on study treatment 15 months

"What impressed me the most is the high complete remission rate, which continues to improve with time, and yet it is the safest drug we have for mantle cell lymphoma," Wang said. "Previously such a rate could be achieved only with combination cyto-reductive chemotherapy, which is bone marrow suppressive and toxic."

Most side effects were minor and included diarrhea, fatigue, upper respiratory tract infections, nausea and rash. Grade 3 or higher effects included low white cell blood counts, anemia and diarrhea. One case of pneumonia was thought to be treatment-related. This was consistent with safety data previously reported, Wang said.

A pivotal study in relapsed and refractory MCL patients following bortezomib treatment has begun.

Pharmacyclics, Inc., which developed ibrutinib, sponsored the clinical trial.

Clinical trial collaborators and co-authors are Jorge Romaguera, M.D., also of MD Anderson's Department of Lymphoma and Myeloma, Simon Rule, M.D., of Derriford Hospital, Plymouth, United Kingdom; Peter Martin, M.D., Weill-Cornell Medical College, New York; Andre Goy, M., John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, N.J.; Rebecca Auer, M.D., Barts Cancer Institute, Queen Mary University of London; Brad Kahl, M.D., University of Wisconsin School of Medicine, Madison, Wisc.; Wojciech Jurczak, M.D., Jagiellonian University, Krakow, Poland; Ranjana Advani M.D., Stanford University School of Medicine; Jesse McGreivy, M.D., Fong Clow, Sc.D., Michelle Stevens-Brogan, and Lori Kunkel, M.D. all of Pharmacyclics, and Kristie Blum, M.D. of The Ohio State University, Columbus, Ohio.

All academic institution co-authors receive research funding from Pharmacyclics. The company's co-authors all have an equity ownership in Pharmacyclics.


Story Source:

The above story is based on materials provided by University of Texas M. D. Anderson Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

University of Texas M. D. Anderson Cancer Center. "Ibrutinib has 'unprecedented' impact on mantle cell lymphoma." ScienceDaily. ScienceDaily, 14 December 2012. <www.sciencedaily.com/releases/2012/12/121214190837.htm>.
University of Texas M. D. Anderson Cancer Center. (2012, December 14). Ibrutinib has 'unprecedented' impact on mantle cell lymphoma. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2012/12/121214190837.htm
University of Texas M. D. Anderson Cancer Center. "Ibrutinib has 'unprecedented' impact on mantle cell lymphoma." ScienceDaily. www.sciencedaily.com/releases/2012/12/121214190837.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins